Hans Scientific — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

HANS Scientific is a private, revenue-generating pharmaceutical CMO and equipment manufacturer leveraging a 27-acre campus in Michigan. Its core business combines traditional contract manufacturing services with proprietary, patent-protected technology for producing Water for Injection (WFI) and advanced water purification systems. The company is in a significant growth phase, backed by a multi-billion dollar investment to expand capacity, aiming to address supply chain vulnerabilities and increasing demand for reliable pharmaceutical manufacturing and critical utilities within the United States.

Technology Platform

Proprietary, high-capacity Water for Injection (WFI) production and modular water purification systems featuring patent-pending technology for efficiency and reliability.

Opportunities

Capitalizing on the strong push for U.S.-based pharmaceutical manufacturing (reshoring) to build supply chain resilience.

Leveraging its proprietary, high-efficiency Water for Injection (WFI) technology to address a critical bottleneck and quality concern in biologics manufacturing, creating a differentiated, integrated service offering.

Risk Factors

Execution risk associated with its massive $2 billion capacity expansion, including potential for delays and cost overruns.

Commercialization risk that market demand will not meet the new capacity, facing intense competition from established global CMOs.

Financial risk inherent in a capital-intensive build-out without public financial disclosures.

Competitive Landscape

Operates in the highly competitive pharmaceutical CMO market, competing against large global players (e.g., Lonza, Catalent, Thermo Fisher) and other U.S.-based CDMOs. Its water systems business faces competition from specialized water technology firms (e.g., SUEZ, Veolia, DuPont) and equipment suppliers serving the biopharma market. Its integrated model is a key differentiator.

More companies in Small Molecule Drugs →More companies in United States →